Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Status unconfirmed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00053105

Run by

Theradex

Starts

2002-02-01

Last updated by the study team

2009-07-07

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Clinical Research Center — Tucson, Arizona, United States
• Highlands Oncology Group — Springdale, Arkansas, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Marlene and Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Ireland Cancer Center — Cleveland, Ohio, United States
• Boston Baskin Cancer Group, University Tennessee — Memphis, Tennessee, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.